Unilateral Chronic Parotitis With 68 Ga-DOTA-FAPI-04 PET/CT and 18 F-FDG PET/CT Imaging in a Case of a Patient With Papillary Thyroid Carcinoma.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
8
11
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
The 68 Ga-FAPI (fibroblast activation protein inhibitor) radiotracer is a novel and versatile tool in nuclear medicine, exhibiting potential for use in various conditions due to its significant upregulation in cancerous and inflammatory conditions, particularly those involving fibrotic and infectious processes. In this report, we present the case of a patient with papillary thyroid carcinoma who underwent total thyroidectomy and iodine therapy. He was referred because of high thyroglobulin despite negative diagnostic radioiodine imaging (TENIS syndrome). The patient underwent 18 F-FDG and 68 Ga-DOTA-FAPI-46 PET/CT imaging for metastatic workup and treatment planning. FAPI uptake was observed in the right parotid gland (with no FDG uptake), prompting a 99m TcO 4- salivary scintigraphy. Subsequently, a diagnosis of chronic sialadenitis was made.
Identifiants
pubmed: 37756475
doi: 10.1097/RLU.0000000000004884
pii: 00003072-990000000-00727
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
68Ga-FAPI
0
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
1HTE449DGZ
Iodine Radioisotopes
0
Gallium-68
98B30EPP5S
Gallium Radioisotopes
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e577-e579Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Avram AM, Giovanella L, Greenspan B, et al. SNMMI procedure standard/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J Nucl Med . 2022;63:15N–35N.
Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw . 2010;8:1277–1287.
Van Nostrand D, Freitas JE, Sawka AM, et al.: Side effects of 131 I for therapy of differentiated thyroid carcinoma. In: Wartofsky L, van Nostrand D, eds. Thyroid Cancer . New York: Springer; 2016:671–708.
Mendoza A, Shaffer B, Karakla D, et al. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid . 2004;14:133–140.
Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med . 2009;50:1605–1610.
Naeimi M, Choyke PL, Dendl K, et al. Three-time-point PET analysis of 68 Ga-FAPI-46 in a variety of cancers. J Nucl Med . 2023;64:618–622.
Kuwert T, Schmidkonz C, Prante O, et al. FAPI PET opens a new window to understanding immune-mediated inflammatory diseases. J Nucl Med . 2022;63:1136–1137.
Roustaei H, Kiamanesh Z, Askari E, et al. Could fibroblast activation protein (FAP)–specific radioligands be considered as pan-tumor agents? Contrast Media Mol Imaging . 2022;2022:3948873.
Treglia G, Muoio B, Roustaei H, et al. Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [ 18 F]F-FDG in oncology: a systematic review. Int J Mol Sci . 2021;22:11192.
Dendl K, Koerber SA, Kratochwil C, et al. FAP and FAPI-PET/CT in malignant and non-malignant diseases: a perfect symbiosis? Cancer . 2021;13:4946.
Kosari HM, Kiamanesh Z, Sadeghi R, et al. Interesting findings in 68 Ga-FAPI-46 PET/CT imaging in a patient with glioblastoma multiforme. Clin Nucl Med . 2023;48:e126–e127.
Xu T, Zhang Y, Wu R, et al. 68 Ga-DOTA-FAPI-04 PET/CT imaging in a case of radioactive iodine–induced chronic parotitis. Clin Nucl Med . 2022;47:1082–1083.